Insights - Teva Pharmaceuticals (TEVA) purchased Auspex Pharmaceuticals this spring for $3.5 billion, primarily for access to the developmental SD-809 (deutetrabenazine), which was in mid-stage studies for the treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. But the larger pharma company has a competitor nipping at its heels.
Read nowResearch - It's not easy. But the good news is - you don't have to.
Read nowInsights - After repeat attempts to convince the U.S. FDA that the company should not be required to run another clinical trial, it appears AcelRx Pharmaceuticals (ACRX) may have finally … Continue Reading
Read nowInsights - Amicus Therapeutics (FOLD), long implicated as an acquisition target by its investors, will do some acquiring of its own. Amicus announced early Monday that it will buy … Continue Reading
Read nowInsights - Following the release of minutes from the Fed’s July Open Market Committee (FOMC) meeting on Wednesday, U.S. markets opened lower and continued lower in early … Continue Reading
Read nowResearch - FDA confirms that LDL-C remains a viable surrogate endpoint for cholesterol-lowering drugs. ETC-1002 does not need a cardiovascular outcomes study prior to approval, and -1002 should be … Continue Reading
PremiumResearch - On Affimed's trial delay and Marinus' three-month performance.
Premium
